Concepedia

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

Daniel Jones, Jennifer A. Woyach, Weiqiang Zhao, Sarah Caruthers, Huolin Tu, J Coleman, John C. Byrd, Amy J. Johnson, Gerard Lozanski

Leukemia · 2017 · 70 citations · 10 references

DOI

Concepts

References

10

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

, , +14

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

C. Lucas, Hye Sun Kuehn, Fang Zhao et al. · Nature Immunology · 2013 · 664 citations

, , +15

<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn et al. · Journal of Clinical Oncology · 2017 · 471 citations

, , +16

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Jan A. Burger, Dan A. Landau, Amaro Taylor‐Weiner et al. · Nature Communications · 2016 · 346 citations · Full text

, , +17

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Inhye E. Ahn, Chingiz Underbayev, Adam Albitar et al. · Blood · 2017 · 342 citations · Full text

, , +14